HGS Cuts High Dose Albuferon In Phase III After Increased Pulmonary Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Lower 900 mcg dose of albinterferon alfa-2b is on track for hepatitis C filing in fall 2009, Human Genome Sciences says.
You may also be interested in...
Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince
Final Phase III study of Human Genome Sciences/Novartis' hepatitis C drug meets primary endpoint, but Pegasys does better numerically, leading to poor reception on the Street.
Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince
Final Phase III study of Human Genome Sciences/Novartis' hepatitis C drug meets primary endpoint, but Pegasys does better numerically, leading to poor reception on the Street.
ACHIEVE-1 Study Shows Albuferon Non-Inferior To Pegasys; Questions Remain
With the March 9 release of the initial results of ACHIEVE-1, the final Phase III trial of Human Genome Sciences/Novartis' pegylated interferon Albuferon, Wall Street analysts have started to question the hepatitis C drug's market value. The trial failed to deliver outstanding efficacy results, and showed some signs of safety problems